High P/S ratio for Shanghai Allist Pharmaceuticals could dis...
High P/S ratio for Shanghai Allist Pharmaceuticals could discourage investors if revenue growth slows. Analysts question sustainability of current P/S ratio, suggesting share price may struggle unless significant industry outperformance.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more